UBM — Ulisse Biomed Spa Share Price
- €18.90m
- €18.11m
- €0.07m
- 39
- 20
- 23
- 14
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 0.76 | ||
Price to Tang. Book | 5.25 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 44.9 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -17.7% | ||
Return on Equity | -31.17% | ||
Operating Margin | -1098.88% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | €m | 0.01 | 0.43 | 0.28 | 0.14 | 0.07 | 1.3 | 1.92 | n/a |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Ulisse Biomed Spa is an Italy-based company engaged in the healthcare biotech sector. The Company focuses on creating new and transformative diagntostic platforms and products. It creates diagnostic systems that can reach people directly and help increasing the frequency of health monitoring. Its platforms include Sagitta, NanoHybrid and Aptavir. Sagitta is a molecular diagnostics technology platform, capable of detecting and characterizing nucleic acids of viral, bacterial and eukaryotic origin. Sagitta is used to develop assays for Respiratory Viral Panel, Sexually Transmitted Diseases, Infectious Diseases and Oncology. NanoHybrid can be implemented not only to develop diagnostic solutions but also in the field of theranostics: the integration of a diagnostic method with a specific therapeutic intervention aimed at maximizing the effectiveness of the drug, as well as vaccine/immunoterapies monitoring. Aptavir is a platform for the identification and production of antiviral molecules.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- April 9th, 2015
- Public Since
- August 6th, 2021
- No. of Employees
- 245
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Borsa Italiana
- Shares in Issue
- 24,481,934

- Address
- Via Aquileia 17, UDINE, 33100
- Web
- https://ulissebiomed.com/
- Phone
- Auditors
- AUDIREVI SpA
Upcoming Events for UBM
Similar to UBM
Arterra Bioscience SpA
Borsa Italiana
Philogen SpA
Borsa Italiana
FAQ
As of Today at 22:51 UTC, shares in Ulisse Biomed Spa are trading at €0.77. This share price information is delayed by 15 minutes.
Shares in Ulisse Biomed Spa last closed at €0.77 and the price had moved by -48.53% over the past 365 days. In terms of relative price strength the Ulisse Biomed Spa share price has underperformed the FTSE Global All Cap Index by -52.48% over the past year.
There is no consensus recommendation for this security.
Find out moreUlisse Biomed Spa does not currently pay a dividend.
Ulisse Biomed Spa does not currently pay a dividend.
Ulisse Biomed Spa does not currently pay a dividend.
To buy shares in Ulisse Biomed Spa you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €0.77, shares in Ulisse Biomed Spa had a market capitalisation of €18.90m.
Here are the trading details for Ulisse Biomed Spa:
- Country of listing: Italy
- Exchange: MIL
- Ticker Symbol: UBM
Based on an overall assessment of its quality, value and momentum Ulisse Biomed Spa is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Ulisse Biomed Spa is €1.00. That is 29.53% above the last closing price of €0.77.
Analysts covering Ulisse Biomed Spa currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ulisse Biomed Spa. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -20.26%.
As of the last closing price of €0.77, shares in Ulisse Biomed Spa were trading -17.65% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Ulisse Biomed Spa PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €0.77.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Ulisse Biomed Spa's directors